Bio-Rad Introduces Liquichek Maternal Serum 1st Trimester Control
HERCULES, CA –November, 2013 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announces the launch of Liquichek™ Maternal Serum 1st Trimester Control.
Liquichek Maternal Serum 1st Trimester Control is a third party control that provides an unbiased and independent assessment of the laboratory’s test methods. It is not optimized to work with any specific instrument or reagent system. The analyte assigned values for many of the more popular test methods are provided in the product insert.
This product is not available for distribution in the United States.
The Unity™ Interlaboratory Program and Unity™ QC Data Management Solutions, designed to improve the effectiveness of the laboratory’s statistical process control, are available for use with Liquichek Maternal Serum 1st Trimester Control.
For more information, please call 1-800-224-6723 or visit www.bio-rad.com/iacontrols.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,600 people worldwide and had revenues exceeding $2 billion in 2012. Visit us at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
Anna Riviere, Product Manager
Bio-Rad Laboratories, Inc.